Literature DB >> 21606168

Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.

Masao Nakagawa1, Shinobu Tsuzuki, Keiichiro Honma, Osamu Taguchi, Masao Seto.   

Abstract

BACKGROUND: A synergistic effect resulting from a combination of BCL2 and MYC or MYC and CCND1 has been implicated in human B-cell lymphomas. Although the identification of other cooperative genes involved is important, our present understanding of such genes remains scant. The objective of this study was to identify the additional cooperative gene(s) associated with BCL2 and MYC or MYC and CCND1. First, we assessed whether Bcl2, Myc and Ccnd1 could cooperate. Next, we developed a synergism-based functional screening method for the identification of other oncogene(s) that act with Bcl2 and Myc. DESIGN AND METHODS: Growth in culture, colony formation and oncogenicity in vivo were assessed in mouse primary B cells exogenously expressing various combinations of Bcl2, Myc and Ccnd1. For the functional screening, Bcl2- and Myc-expressing primary B cells were infected with a retroviral cDNA library. Inserted cDNA of transformed cells in culture were then identified.
RESULTS: Primary B cells exogenously expressing Bcl2, Myc and Ccnd1 showed factor-independent growth ability, enhanced colony-forming capability and aggressive oncogenicity, unlike the cases observed with the expression of any combination of only two of the genes. We identified CCND3 and NRAS as cooperative genes with Bcl2 and Myc through the functional screening.
CONCLUSIONS: Bcl2, Myc and Ccnd1 or Bcl2, Myc and CCND3 synergistically transformed mouse primary B cells into aggressive malignant cells. Our new synergism-based method is useful for the identification of synergistic gene combinations in tumor development, and may expand our systemic understanding of a wide range of cancer-causing elements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606168      PMCID: PMC3166102          DOI: 10.3324/haematol.2011.041053

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  41 in total

Review 1.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 2.  The Bcl2 family: regulators of the cellular life-or-death switch.

Authors:  Suzanne Cory; Jerry M Adams
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 3.  Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics.

Authors:  Toshio Kitamura; Yuko Koshino; Fumi Shibata; Toshihiko Oki; Hideaki Nakajima; Tetsuya Nosaka; Hidetoshi Kumagai
Journal:  Exp Hematol       Date:  2003-11       Impact factor: 3.084

4.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

5.  Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.

Authors:  T Sonoki; L Harder; D E Horsman; L Karran; I Taniguchi; T G Willis; S Gesk; D Steinemann; E Zucca; B Schlegelberger; F Solé; A J Mungall; R D Gascoyne; R Siebert; M J Dyer
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

6.  Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.

Authors:  Martin Filipits; Ulrich Jaeger; Gudrun Pohl; Thomas Stranzl; Ingrid Simonitsch; Alexandra Kaider; Cathrin Skrabs; Robert Pirker
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

7.  Case of B-cell lymphoma with rearrangement of the BCL1, BCL2, BCL6, and c-MYC genes.

Authors:  Keiki Kawakami; Setsuko Miyanishi; Takashi Sonoki; Shigeo Nakamura; Kenichi Nomura; Masafumi Taniwaki; Tetsuya Murata; Shigenori Kadowaki; Norimitsu Kadowaki; Ikuo Miura
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 8.  c-MYC: more than just a matter of life and death.

Authors:  Stella Pelengaris; Mike Khan; Gerard Evan
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

9.  Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.

Authors:  Shinobu Tsuzuki; Masao Seto; Mel Greaves; Tariq Enver
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-20       Impact factor: 11.205

10.  Development of mice expressing a single D-type cyclin.

Authors:  Maria A Ciemerych; Anna M Kenney; Ewa Sicinska; Ilona Kalaszczynska; Roderick T Bronson; David H Rowitch; Humphrey Gardner; Piotr Sicinski
Journal:  Genes Dev       Date:  2002-12-15       Impact factor: 11.361

View more
  9 in total

1.  Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model.

Authors:  K Arita; S Tsuzuki; K Ohshima; T Sugiyama; M Seto
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

2.  MicroRNA profiling of CD3+ CD56+ cytokine-induced killer cells.

Authors:  Wenju Wang; Ruhong Li; Mingyao Meng; Chuanyu Wei; Yanhua Xie; Yayong Zhang; Lihong Jiang; Ruiyi Dong; Chunhui Wang; Yiming Zhong; Fang Yang; Weiwei Tang; Xingfang Jin; Baohua Liu; Zongliu Hou
Journal:  Sci Rep       Date:  2015-03-31       Impact factor: 4.379

3.  Inferring gene dependency network specific to phenotypic alteration based on gene expression data and clinical information of breast cancer.

Authors:  Xionghui Zhou; Juan Liu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

4.  Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.

Authors:  Taishi Takahara; Keitaro Matsuo; Masao Seto; Shigeo Nakamura; Shinobu Tsuzuki
Journal:  Cancer Sci       Date:  2016-11-04       Impact factor: 6.716

5.  Identifying prognostic signature in ovarian cancer using DirGenerank.

Authors:  Jian-Yong Wang; Ling-Ling Chen; Xiong-Hui Zhou
Journal:  Oncotarget       Date:  2017-07-11

6.  Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model.

Authors:  Lorenz Loyola; Vasudevan Achuthan; Kathryn Gilroy; Gillian Borland; Anna Kilbey; Nancy Mackay; Margaret Bell; Jodie Hay; Sriram Aiyer; Dylan Fingerman; Rodrigo A Villanueva; Ewan Cameron; Christine A Kozak; Alan N Engelman; James Neil; Monica J Roth
Journal:  PLoS Pathog       Date:  2019-12-09       Impact factor: 6.823

Review 7.  Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.

Authors:  Joanna C Dawes; Anthony G Uren
Journal:  Front Immunol       Date:  2021-08-13       Impact factor: 7.561

8.  Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.

Authors:  Kiyoko Yamamoto; Shinobu Tsuzuki; Yosuke Minami; Yukiya Yamamoto; Akihiro Abe; Koichi Ohshima; Masao Seto; Tomoki Naoe
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

9.  RET rearrangements are actionable alterations in breast cancer.

Authors:  Bhavna S Paratala; Jon H Chung; Casey B Williams; Bahar Yilmazel; Whitney Petrosky; Kirstin Williams; Alexa B Schrock; Laurie M Gay; Ellen Lee; Sonia C Dolfi; Kien Pham; Stephanie Lin; Ming Yao; Atul Kulkarni; Frances DiClemente; Chen Liu; Lorna Rodriguez-Rodriguez; Shridar Ganesan; Jeffrey S Ross; Siraj M Ali; Brian Leyland-Jones; Kim M Hirshfield
Journal:  Nat Commun       Date:  2018-11-16       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.